Featured Research

from universities, journals, and other organizations

Immune system's guard against cancer: How immuno-messenger substances can inhibit tumour growth

Date:
April 6, 2010
Source:
Helmholtz Centre for Infection Research
Summary:
The human body has developed various mechanisms, through which it can protect itself against newly-developing cancer cells. For instance, killer-cells recognize and destroy altered cells in our organs every day. Once tumors have developed, they may be inhibited in growth by messenger substances from the immune system. Scientists have now succeeded to reveal a completely unexpected function of such an immunological messenger substance in the suppression of tumors -- the molecule beta-interferon inhibits the tumor in its attempts to connect into the human blood circulatory system. Moreover, it hinders the production of growth factors that support the formation of new blood vessels. The conclusion: the tumor cannot grow.

The connection with the blood circulatory system is a significant step in the development of cancer.

Related Articles


Within the tissue where it is growing, the tumour develops an independent existence. With signal substances it entices white blood cells from the bone marrow into the tumour tissue. The task of these cells, usually, is to defend against infection and stimulate the healing of wounds. Within the tumour, these cells prompt new blood vessels to increase their rate of growth. Once the tumour is connected to the blood circulatory system, it is provided with nutrients for growth. It also can then disseminate its own cells into the overall blood circulatory system as well and form metastases.

Scientists at the Helmholtz Centre for Infection Research are now in the process of deciphering precisely how a messenger substance is able to inhibit this integration process into the blood circulatory system.

Messenger substances are the fine-tuning regulators of immune-cells; they activate or deactivate them, generate the production of growth factors or further messenger substances and initiate or terminate an immune reaction. One of these signal molecules is currently being used in therapy for several forms of cancer -interferon. How it works remains a mystery, so far, to scientists. Research scientist Jadwiga Jablonska from HZI has recently found a new mode of action against cancer beta-interferon a subtype of the interferons. The results surprised her: "Beta-interferon blocks the connection of the tumour into the blood vessel system by inhibiting immune cells to produce growth factors. This effect upon tumours was completely unexpected," says Jadwiga Jablonska.

The research scientist allowed skin tumours to grow in two groups of mice; the first group of mice was not able to build beta-interferon, while the second group produced the messenger substance as usual within their bodies. After a few days, the research scientist investigated the growth rate of the tumour. "In mice that cannot produce beta-interferon, the tumours were considerably larger than in the animals that did have the signal molecule in their bodies." With beta-interferon, the tumours not only grew slower -- they formed fewer and smaller metastases as well.

The reason for the inferior rate of growth was found by the research scientist to be attributable to the lack of blood circulation within the tumours. "In the presence of beta-interferon, considerably fewer blood vessels developed within the tumour," says Jadwiga Jablonska. The beta-interferon functioned through a small detour; it blocked the formation of vessel producing growth factors in cells that were enticed by the tumour to promote the connection with the blood-circulatory system. The research scientist discovered that the cells not only formed fewer growth factors, a smaller quantity of these cells found their way into the tumour, as well. "Only a negligible quantity of this messenger substance was sufficient to keep cells at bay and to inhibit growth factors, thus arresting the growth of tumours," says Jadwiga Jablonska.

"This mode of action on the part of beta-interferon had previously been unidentified," says Siegfried Weiss, leader of the working group "Molecular Immunology" at HZI. The messenger substance actually plays a significant role in viral diseases and reactions to infections. "We now are attempting to understand how the network of tumour, immune cells and messenger substance functions, in order to discover new target structures for cancer therapy," says Weiss.


Story Source:

The above story is based on materials provided by Helmholtz Centre for Infection Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jadwiga Jablonska, Sara Leschner, Kathrin Westphal, Stefan Lienenklaus, Siegfried Weiss. Neutrophils responsive to endogenous IFN-%u03B2 regulate tumor angiogenesis and growth in a mouse tumor model. Journal of Clinical Investigation, 2010; DOI: 10.1172/JCI37223

Cite This Page:

Helmholtz Centre for Infection Research. "Immune system's guard against cancer: How immuno-messenger substances can inhibit tumour growth." ScienceDaily. ScienceDaily, 6 April 2010. <www.sciencedaily.com/releases/2010/04/100406074639.htm>.
Helmholtz Centre for Infection Research. (2010, April 6). Immune system's guard against cancer: How immuno-messenger substances can inhibit tumour growth. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2010/04/100406074639.htm
Helmholtz Centre for Infection Research. "Immune system's guard against cancer: How immuno-messenger substances can inhibit tumour growth." ScienceDaily. www.sciencedaily.com/releases/2010/04/100406074639.htm (accessed March 31, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, March 31, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins